Dishman named to direct PMI Cohort Program

The National Institutes of Health has selected Eric Dishman to head the Precision Medicine Initiative (PMI) Cohort Program. The PMI Cohort Program seeks to extend precision medicine to all diseases by building a national research cohort of at least 1 million U.S. participants. The cohort is a key element of President Obama's Precision Medicine Initiative, announced in January 2015. 

PMI takes into account individual variability in genes, environment and lifestyle when designing treatment for disease. By taking into account the biological, environmental and behavioral influences on on diseases, researchers hope to enable a new era of medicine in which researchers, providers and patients work together to develop individualized treatment plans.

 

Prior to his appointment at NIH, Dishman was Vice President and Intel Fellow of Intel Corporation's Health & Life Sciences Group, leading Intel's healthcare strategy and research.  He also was a key member of the Precision Medicine Working Group, which spent several months in 2015 developing the design for the PMI study.

"Eric will lead NIH’s effort to build the PMI landmark longitudinal research study of one million or more U.S. volunteers to expand our ability to improve health and treat disease through precision medicine," NIH Director Francis S. Collins said in the announcement of Dishman's appointment. "Eric brings a wealth of health innovation experience to the PMI effort — as a social scientist and researcher, entrepreneur and business leader, patient and patient advocate, and policy advocate and thought leader."